Dako HercepTest与Ventana PATHWAY抗HER2（4B5）检测在肺腺癌中的比较及其与银染杂交的相关性
Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver hybridization in lung adenocarcinoma.
作者信息
Miladinović Mirjana, Vučković Ljiljana, Klisic Aleksandra
机构信息
Department of Pathology, Clinical Center of Montenegro, University of Montenegro-Faculty of Medicine, Podgorica, Montenegro.
Center for Laboratory Diagnostics, Primary Health Care Center, University of Montenegro-Faculty of Medicine, Trg Nikole Kovacevica 6, 81000 Podgorica, Montenegro.
出版信息
Open Med (Wars). 2021 Oct 6;16(1):1503-1512. doi: 10.1515/med-2021-0366. eCollection 2021.
BACKGROUND
Discordant results exist about the role of human epidermal growth factor receptor 2 (HER2) overexpression and/or HER2 amplification in lung adenocarcinoma. We aimed to compare the performance of HercepTest and PATHWAY anti-HER2 (4B5) by correlating immunohistochemistry (IHC) results with silver hybridization (SISH) in adenocarcinoma lung specimens.
METHODS
A total of 148 surgically resected adenocarcinoma lung specimens were included.
RESULTS
HER2 overexpression was found in 7.4% patients for HercepTest Dako and in 2.7% patients for 4B5 antibody. The overall coincidence between these two types of antibodies equals 93.9%. The incidence of HER2 amplification in lung adenocarcinoma was 17.6%, of which in 2.7% of the cases high-grade amplification was present. HER2 amplification was present in 90.9% of patients with overexpression of HER2, obtained by using HercepTest Dako and 75% patients using 4B5 antibody. A significant correlation between overexpression of HER2 receptors obtained by HercepTest Dako and 4B5 antibody and HER2 amplification was shown.
CONCLUSION
The research of the efficiency of targeted molecular therapies with an HER2 antibody may serve as a basis for the introduction of routine HER2 status determination in lung adenocarcinoma, dictating the need for the standardized protocol for HER2 status determination in such pathology.
背景
关于人表皮生长因子受体2（HER2）过表达和/或HER2扩增在肺腺癌中的作用，存在不一致的结果。我们旨在通过将免疫组织化学（IHC）结果与肺腺癌标本中的银染原位杂交（SISH）结果相关联，比较HercepTest和PATHWAY抗HER2（4B5）的性能。
方法
共纳入148例手术切除的肺腺癌标本。
结果
对于HercepTest Dako，7.4%的患者发现HER2过表达；对于4B5抗体，2.7%的患者发现HER2过表达。这两种抗体之间的总体符合率为93.9%。肺腺癌中HER2扩增的发生率为17.6%，其中2.7%的病例存在高级别扩增。使用HercepTest Dako检测到HER2过表达的患者中，90.9%存在HER2扩增；使用4B5抗体检测到HER2过表达的患者中，75%存在HER2扩增。通过HercepTest Dako和4B5抗体获得的HER2受体过表达与HER2扩增之间存在显著相关性。
结论
用HER2抗体进行靶向分子治疗效率的研究，可为在肺腺癌中引入常规HER2状态检测提供依据，表明在这种病理情况下需要有标准化的HER2状态检测方案。
Zotero 插件